You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ):獲同意提交境外完成的BE研究數據用於達比加羣酯膠囊上市申請
格隆匯 03-31 15:43

格隆匯3月31日丨海思科(002653.SZ)公佈,之前公告披露,公司全資子公司四川海思科製藥有限公司於近日收到國家藥品監督管理局下發的達比加羣酯膠囊膠囊《臨牀試驗通知書》(其於2020年年初獲得國家藥品監督管理局受理)。

根據《中華人民共和國藥品管理法》及有關規定,經審查,達比加羣酯膠囊(受理號:JXHL1900374、JXHL1900375)符合藥品註冊的有關要求,同意申請人提交境外完成的BE研究數據用於本品上市申請。公司將按要求儘快完成相應研究工作後申報該產品上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account